bluebird bio is a clinical-stage biotechnology company that develops gene therapies for severe genetic and rare diseases. The company's gene therapy procedures aim to genetically modify a patient's cells to fundamentally correct or address the genetic basis underlying a disease. Bluebird's revenue is derived from collaboration arrangements, research fees, license fees, and grant revenue. The company works with industry peers, strategic partners, and nonprofit organizations for the development and commercialization of its product candidates.

Research Grants 3 show all


$142K
2003

$249.7K
2008

Patents 466show all

  • 78
    A61K - Preparations for medical, dental, or toilet purposes
  • 64
    C12N - Microorganisms or enzymes
  • 40
    C07K - Peptides
  • 26
    G06F - Electric digital data processing
  • 17
    H04M - Telephonic communication
  • 12
    A01K - Animal husbandry
  • 11
    H04B - Transmission
  • 11
    H05K - Printed circuits
  • 9
    C07H - Sugars
  • 7
    A61P - Specific therapeutic activity of chemical compounds or medicinal preparations

Clinical Trials 36show all

22Phase 35Phase 1/Phase 22Phase 12Phase 2/Phase 32Other

SEC Filings show all


156
8-K

21
10-Q

7
10-K

4
D

1
S-1

Contact Information

150 Second Street Third Floor
Cambridge, MA 02141
United States

Overview

Total FundingEmployeesLast Funding DateStatus
$409,000,000501-10002016-12-07Ipo

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2016-12-07$250,000,000Post Ipo Equity
2012-07-25$60,000,000Series DArmaVir Partners, ARCH Venture Partners, Deerfield Partners, Forbion Capital Partners, Third Rock Ventures, TVM Capital, RA Capital Management
2004-10-07$12,000,000Series UnknownTechno Venture ManagementABN AMRO Fund, Easton Capital
2010-03-12$35,000,000Series BSanofi-Genzyme BioVentures, Third Rock VenturesForbion Capital Partners, Easton Capital, TVM Capital
2012-10-27$9,300,000Series UnknownCalifornia Institute for Regenerative Medicine
2011-04-20$30,000,000Series CARCH Venture PartnersForbion Capital Partners, Easton Capital, Third Rock Ventures, TVM Capital
2011-03-16$4,200,000Grant
2004-06-17$8,500,000Series ANazem and Company, ABN AMRO Fund

SEC Form D Funding Events

DateOfferedSoldType
2012-07-25$60,000,000$60,000,000Equity
2011-04-27$37,500,000$37,500,000Equity, Option to Acquire, Security to be Acquired
2011-04-27$30,000,000$15,000,000Equity
2007-05-17Unknown Unknown Other (Paper Filing)

Key Executives

  • Nick Leschly
    Executive Officer, Director
  • Axel Polack
    Director
  • Steven Gillis
    Director
  • Geert-Jan Mulder
    Director
  • Robert Tepper
    Director
  • Daniel S. Lynch
    Director
  • John M. Maraganore
    Director
  • Jeffrey T. Walsh
    Executive Officer